



Achillion Pharmaceuticals  
Investor Relations Department  
300 George St.  
New Haven, CT 06511  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ACHN**

Last Trade: 3.20

Trade Time: 4:00 PM ET  
Feb 16, 2018

Change: 0.13 ↑ (+4.235%)

Day Range 3.07 - 3.24

52-Week Range 2.58 - 5.66

Volume 8,034,929

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 9, 2018*

[Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference](#)

*Dec 20, 2017*

[Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D](#)

*Dec 18, 2017*

[Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy \(C3G\) and the Initiation of a Phase 1 Extended-Release Bioavailability Study](#)

*Nov 15, 2017*

[Achillion Announces Pricing of Secondary Offering Of Common Stock](#)

*Nov 14, 2017*

[Achillion Announces Proposed Secondary Offering of Common Stock](#)

## Financial Disclosures [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Feb 23, 2017*

[Annual Report \(10-K\)](#)

*Apr 17, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 1, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2017*

[Quarterly Report \(10-Q\)](#)

*May 4, 2017*

[Quarterly Report \(10-Q\)](#)